secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2023-08-21T23:59:59+00:00
Accession:  0001356576-23-000056
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus appoints Bethany L. Sensenig to Board of Directors
-----------------------------------------------------------

- Ms. Sensenig appointed as independent director and Audit Committee member effective August 17, 2023.
- 2023 compensation: $62,500 prorated for service plus options to buy 24,153 shares at $30.22 (4-year vest).
- Board expands to seven members; Ms. Sensenig brings 20+ years pharma/biotech financial leadership.
- Former CFO/Interim CEO of 9 Meters Biopharma and VP Finance & Commercial Ops at Biogen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657623000056/0001356576-23-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657623000056/supn-20230817.htm
  HTML page:      https://secwatch.observer/filing/0001356576-23-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer